Biomea Fusion, Inc. (BMEA) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -58.06M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 40.78M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-58.06M | (m) | (m) | $40.78M | (m) | (m) |
| 2026-03-31 | $-66.57M | (m) | (m) | $48.20M | (m) | (m) |
| 2025-12-31 | $-83.51M | (m) | (m) | $61.98M | (m) | (m) |
| 2025-09-30 | $-101.87M | (m) | (m) | $79.10M | (m) | (m) |
| 2025-06-30 | $-115.10M | (m) | (m) | $91.95M | (m) | (m) |
| 2025-03-31 | $-132.72M | (m) | (m) | $107.21M | (m) | (m) |
| 2024-12-31 | $-144.07M | (m) | (m) | $118.08M | (m) | (m) |
| 2024-09-30 | $-151.32M | (m) | (m) | $123.71M | (m) | (m) |
| 2024-06-30 | $-148.40M | (m) | (m) | $121.81M | (m) | (m) |
| 2024-03-31 | $-137.16M | (m) | (m) | $111.93M | (m) | (m) |
| 2023-12-31 | $-126.14M | (m) | (m) | $102.55M | (m) | (m) |
| 2023-09-30 | $-115.08M | (m) | (m) | $92.22M | (m) | (m) |
| 2023-06-30 | $-107.45M | (m) | (m) | $85.11M | (m) | (m) |
| 2023-03-31 | $-97.27M | (m) | (m) | $75.76M | (m) | (m) |
| 2022-12-31 | $-83.63M | (m) | (m) | $62.71M | (m) | (m) |
| 2022-09-30 | $-72.09M | (m) | (m) | $53.26M | (m) | (m) |
| 2022-06-30 | $-61.25M | (m) | (m) | $42.91M | (m) | (m) |
| 2022-03-31 | $-52.21M | (m) | (m) | $35.55M | (m) | (m) |
| 2021-12-31 | $-41.67M | (m) | (m) | $28.00M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-5.33M | (m) | (m) | $3.67M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-1.20M | (m) | (m) | $1.09M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |